
ARDT Stock Forecast & Price Target
ARDT Analyst Ratings
Bulls say
Ardent Health Inc. demonstrated a significant financial performance with EBITDA increasing by 46% year-over-year to $143 million, accompanied by an improved margin of 9.1%, marking a 240 basis point rise. The company also experienced a 5.8% year-over-year growth in inpatient admissions, outperforming the peer average of 1.7%, indicating strong demand for its services. Despite challenges with professional fees, management anticipates that ongoing investment in technologies and services, along with an expected uptick in capital expenditures, will contribute positively to future growth.
Bears say
Ardent Health Inc's financial outlook appears negative due to a combination of disappointing EBITDA performance and challenges in revenue management. The company experienced a 2% miss on EBITDA expectations, exacerbated by a shift in revenue recognition related to its transition to a new revenue cycle management platform, which has resulted in conservative assumptions regarding accounts receivable collectability. Additionally, ongoing issues with increased claims denials and professional fee pressures are projected to lead to minimal or negative EBITDA growth in 2026, significantly lowering EBITDA-NCI estimates for both 2025 and 2026.
This aggregate rating is based on analysts' research of Ardent Health Partners LLC and is not a guaranteed prediction by Public.com or investment advice.
ARDT Analyst Forecast & Price Prediction
Start investing in ARDT
Order type
Buy in
Order amount
Est. shares
0 shares